Updated American Cancer Society HPV vaccine guideline seeks to reinforce key messages

“A little over a third of young people have received both doses the vaccine by age 13, and between 50% 60% teens ages 13 to 17 recommended doses, with two-thirds having at least first dose,” says Dr. Saslow. She adds that public health goal is drive those numbers closer 80% 90% rates other childhood vaccinations. The ACS leads many efforts aimed achieving goal, including recent update its HPV vaccination guideline. organization issued guideline for routine use in 2007, updated it 2016, released latest version summer 2020 CA: A Cancer Journal Clinicians.1 leaders regularly review their guidelines variety cancer prevention areas, screening, on basis evidence. For this new update, members Guideline Development Group conducted content recommendations Advisory Committee Immunization Practices (ACIP) Centers Disease Control Prevention (CDC). group reviewed studies evaluated ACIP’s interpretations. In issuing emphasized few differences recommendations. First, although ACIP noted fine start vaccinating boys girls 9 years, care providers should be encouraged offering or 10 years children receive 12 years. “There are lot data saying it’s easier doctors systems vaccinate starting 10, American Academy Pediatrics (AAP) recommends routinely these ages,” Saslow says. suggests several reasons why beginning vaccinations more beneficial than waiting until 11 One key reason 9- 10-year-olds likely still attending annual well-child visits comparison who older. Second, parents tend concerns about sexual activity adolescence, whereas issue less brought up when younger. Lastly, due Tdap meningococcal vaccines. original intent CDC was bundle all 3 vaccines together 1 visit, but often not parental preference, notes. fact, she adds, because no scheduled administered aged flu shot, seem receptive time. “Some newer showed they led higher also how were it,” “I’ve been doing talks organizations, they’re really excited it.” believes now AAP made recommendation, will gain further traction among parents. Elise C. Kohn, MD, National Institute (NCI) senior investigator head Gynecologic Therapeutics concurs, saying, “It’s always important multiple voices impacting situation, has worldwide platform make plea broader access.” adults 26 yet vaccinated. agreed added inform 22 may effective lowering risk. Furthermore, another recommendation noting older vaccine, shared decision-making acceptable 27 46 considering it. (The cannot prevent virus if person already infected it, experts emphasize administering younger teens.) did endorse recommendation. “Most won’t benefit,” explains. “We looked same modeling reviewed, [at ages] prevents half percent genital warts cancer. We’re talking maybe preventing dozen cancers per year out 35,000.” partners numerous state, local, national organizations furnish community ongoing education vaccine. society runs CDCfunded Vaccination Roundtable, coalition 70 as well survivors 6 HPV-related cancers. roundtable’s website (https://hpvroundtable.org/) provides clearinghouse information upcoming meetings, outreach campaigns, educational resources. small significant percentage concerned safety, seems targeted, so we safety messages,” one most studied vaccines—there 100 involving millions people.” Unfortunately, just screenings, COVID-19 pandemic significantly set back last year. Although rebounded slightly during closing months year, 1.1 million fewer had since previous “If kids come get affect risk cancer, lost whole cohort don’t back, difference,” Kohn NCI conducting research increase uptake nationally vaccine’s effectiveness deaths from cervical, neck, Globally, women highest lifetime cervical being vaccinated, continues matter pressing concern. example study published Institute.2 Lead researcher Aimée R. Kreimer, PhD, Division Epidemiology Genetics, her colleagues examined long-term follow-up Costa Rica Vaccine Trial determine whether dose areas high disease prevalence. Kreimer reported decade after receipt single-dose against HPV-16 -18 infection, remained antibodies stable trial participants. As result, authors concluded additional necessary provide infection protection.